Inceptua and Portola have entered into an agreement whereby Inceptua will become Portola’s exclusive distribution partner for Ondexxya® in selected countries.
Ondexxya® has been approved by the US FDA, and was also approved by the EMA on 26th April 2019. Ondexxya® (andexanet alfa) is a recombinant modified human factor Xa (FXa) protein intended for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.
Through this agreement Inceptua becomes the exclusive distributor of Ondexxya® in; Belgium, France, Ireland, Luxembourg, Norway, Portugal and Spain. Inceptua Medicines Access will be providing access to Ondexxya® in these countries until the point at which Ondexxya® becomes commercially-available in each country.